Lincoln National Corp’s Lineage Cell Therapeutics LCTX Stock Holding History

Lincoln National Corp’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-156,225	Closed	-$234K	–	1058
2023 Q1	$234K	Buy	156,225 +525	+0.3%	+$733	﹤0.01%	860
2022 Q4	$182K	Sell	155,700 -62,000	-28%	-$78.1K	﹤0.01%	877
2022 Q3	$246K	Sell	217,700 -33,800	-13%	-$49.6K	0.01%	730
2022 Q2	$397K	Buy	251,500 +58,600	+30%	+$77.3K	0.01%	541
2022 Q1	$297K	Sell	192,900 -600	-0.3%	-$931	0.01%	717
2021 Q4	$474K	Buy	193,500 +38,900	+25%	+$91K	0.01%	541
2021 Q3	$390K	Buy	+154,600	New	+$397K	0.01%	585

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Lincoln National Corp's LCTX Position: Q2 2023 in Review

Lincoln National Corp sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 156,225 shares — an estimated $234K sold.

Lincoln National Corp first reported a position in LCTX in Q3 2021 and held it in 7 quarters. The position peaked at $474K in Q4 2021. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

Lincoln National Corp reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
Lincoln National Corp sold 156,225 Lineage Cell Therapeutics shares in Q2 2023, an estimated $234K.
Lincoln National Corp first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 7 quarters.
Lincoln National Corp's Lineage Cell Therapeutics position peaked at $474K in Q4 2021.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Lincoln National Corp's 13F filing for Q2 2023, filed 7 Aug 2023.